http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : Fang Mingxiao (검색결과 2 건)
- 무료
- 기관 내 무료
- 유료
-
FXR Regulates Intestinal Cancer Stem Cell Proliferation
Fu, Ting,Coulter, Sally,Yoshihara, Eiji,Oh, Tae Gyu,Fang, Sungsoon,Cayabyab, Fritz,Zhu, Qiyun,Zhang, Tong,Leblanc, Mathias,Liu, Sihao,He, Mingxiao,Waizenegger, Wanda,Gasser, Emanuel,Schnabl, Bernd,Atk Elsevier 2019 Cell Vol.176 No.5
<P><B>Summary</B></P> <P>Increased levels of intestinal bile acids (BAs) are a risk factor for colorectal cancer (CRC). Here, we show that the convergence of dietary factors (high-fat diet) and dysregulated WNT signaling (APC mutation) alters BA profiles to drive malignant transformations in Lgr5-expressing (Lgr5<SUP>+</SUP>) cancer stem cells and promote an adenoma-to-adenocarcinoma progression. Mechanistically, we show that BAs that antagonize intestinal farnesoid X receptor (FXR) function, including tauro-β-muricholic acid (T-βMCA) and deoxycholic acid (DCA), induce proliferation and DNA damage in Lgr5<SUP>+</SUP> cells. Conversely, selective activation of intestinal FXR can restrict abnormal Lgr5<SUP>+</SUP> cell growth and curtail CRC progression. This unexpected role for FXR in coordinating intestinal self-renewal with BA levels implicates FXR as a potential therapeutic target for CRC.</P> <P><B>Highlights</B></P> <P> <UL> <LI> Genetic and dietary risk factors for colorectal cancer converge on the BA-FXR axis </LI> <LI> FXR controls proliferating Lgr5<SUP>+</SUP> intestinal stem cells </LI> <LI> FXR agonists curtail colorectal cancer progression </LI> </UL> </P> <P><B>Graphical Abstract</B></P> <P>[DISPLAY OMISSION]</P>
-
Zheng Jun,Huang Ju,Zhang Liang,Wang Mengna,Xu Lihong,Dou Xiaoyun,Leng Xiaojing,Fang Mingxiao,Sun Yang,Wang Zhigang 한국생체재료학회 2023 생체재료학회지 Vol.27 No.00
Although programmed cell death protein 1 (PD-1)/ programmed cell death-ligand protein 1 (PD-L1) checkpoint blockade immunotherapy demonstrates great promise in cancer treatment, poor infiltration of T cells resulted from tumor immunosuppressive microenvironment (TIME) and insufficient accumulation of anti-PD-L1 (αPD-L1) in tumor sites diminish the immune response. Herein, we reported a drug-loaded microbubble delivery system to overcome these obstacles and enhance PD-L1 blockade immunotherapy.Docetaxel (DTX) and imiquimod (R837)-loaded microbubbles (RD@MBs) were synthesized via a typical rotary evaporation method combined with mechanical oscillation. The targeted release of drugs was achieved by using the directional "bursting" capability of ultrasound-targeted microbubble destruction (UTMD) technology. The antitumor immune response by RD@MBs combining αPD-L1 were evaluated on 4T1 and CT26 tumor models.The dying tumor cells induced by DTX release tumor-associated antigens (TAAs), together with R837, promoted the activation, proliferation and recruitment of T cells. Besides, UTMD technology and DTX enhanced the accumulation of αPD-L1 in tumor sites. Moreover, RD@MBs remolded TIME, including the polarization of M2-phenotype tumor-associated macrophages (TAMs) to M1-phenotype, and reduction of myeloid-derived suppressor cells (MDSCs). The RD@MBs + αPD-L1 synergistic therapy not only effectively inhibited the growth of primary tumors, but also significantly inhibited the mimic distant tumors as well as lung metastases.PD-L1 blockade immunotherapy was enhanced by RD@MBs delivery system.
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
